First Trust Advisors LP lifted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 85.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,036 shares of the biotechnology company’s stock after acquiring an additional 17,996 shares during the quarter. First Trust Advisors LP owned 0.11% of Repligen Corporation worth $1,618,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Repligen Corporation in the first quarter valued at $103,000. Victory Capital Management Inc. increased its holdings in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares during the last quarter. US Bancorp DE increased its holdings in Repligen Corporation by 1.2% in the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 54 shares during the last quarter. Finally, Benin Management CORP purchased a new position in Repligen Corporation in the second quarter valued at $207,000. 97.91% of the stock is currently owned by institutional investors and hedge funds.
Repligen Corporation (RGEN) opened at 44.32 on Friday. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The firm’s 50 day moving average price is $42.01 and its 200 day moving average price is $38.70. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of 86.73 and a beta of 1.21.
Repligen Corporation (NASDAQ:RGEN) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The company’s revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.16 EPS. Equities analysts forecast that Repligen Corporation will post $0.59 earnings per share for the current year.
Several equities analysts recently commented on RGEN shares. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered Repligen Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. William Blair started coverage on Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating on the stock. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Finally, TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $42.00.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.